CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.52B, above the global median of $1.18B
- PositionOperating margin is 53.4%, higher than 95% of its Biotechnology peers (median -38%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
1.52BUSDvs all stocks (USD)
Revenue (TTM)
106.09MUSDvs all stocks (USD)
Profit Margin
246.96%vs Biotechnology peers
Beta
0.4080xvs all stocks
52-Week Change
228.75%vs all stocks
Market Capitalization
1.52BUSDvs all stocks (USD)
Enterprise Value
1.63BUSDvs all stocks (USD)
Forward P/E
9.21xvs Biotechnology peers
Price to Sales (TTM)
14.37xvs Biotechnology peers
Price to Book (MRQ)
116.17xvs Biotechnology peers
Enterprise to Revenue
15.37xvs Biotechnology peers
Enterprise to EBITDA
24.81xvs Biotechnology peers
Profit Margin
246.96%vs Biotechnology peers
Operating Margin
53.38%vs Biotechnology peers
Return on Assets (TTM)
-3.63%vs Biotechnology peers
Return on Equity (TTM)
-35.56%vs Biotechnology peers
Revenue (TTM)
106.09MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.66USDUpdated Sep 26, 2026Quarterly Revenue Growth
23.50%vs Biotechnology peers
EBITDA (TTM)
69.25MUSDvs all stocks (USD)
Net Income (TTM)
352.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-7.98%vs Biotechnology peers
Operating Cash Flow (TTM)
-105.12MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-13.23MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
234.60MUSDFY2025 · Dec 31, 2025Operating Income
47.90MUSDvs all stocks (USD)
Pre-tax Income
-13.07MUSDFY2025 · Dec 31, 2025Income Tax Expense
164.00KUSDFY2025 · Dec 31, 2025Net Income
-13.23MUSDFY2025 · Dec 31, 2025EBIT
66.83MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
69.25MUSDFY2025 · Dec 31, 2025Research & Development
135.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
50.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
79.89MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
28.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
28.76MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-13.23MUSDFY2025 · Dec 31, 2025Operating Cash Flow
22.82MUSDFY2025 · Dec 31, 2025Free Cash Flow
22.73MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.42M of depreciation against 87K of capital expenditure, and its own free-cash-flow line reads 19.61M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
238.20MUSDFY2025 · Dec 31, 2025Income Tax Paid
78.00KUSDFY2025 · Dec 31, 2025Interest Paid
79.99MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-13.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.42MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
79.89MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
6.92MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-87.33MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.93MUSDFY2025 · Dec 31, 2025Capital Expenditures
-87.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-196.41MUSDFY2025 · Dec 31, 2025Sale of Investments
424.53MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
228.03MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-68.63MUSDFY2025 · Dec 31, 2025Other Financing Charges
-76.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-131.16MUSDFY2025 · Dec 31, 2025Shares Outstanding
29.03MSharesUpdated Sep 26, 2026Float Shares
20.42MSharesUpdated Sep 26, 2026Shares Short
5.44MSharesUpdated Sep 26, 2026Short Ratio
12.32daysvs all stocks
Short % of Shares Outstanding
40.51%vs all stocks
% Held by Insiders
5.68%vs all stocks
% Held by Institutions
106.16%vs all stocks
Total Cash (MRQ)
164.14MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.49USDUpdated Sep 26, 2026Total Debt (MRQ)
269.59MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
25.47xvs Biotechnology peers
Current Ratio (MRQ)
5.61xvs Biotechnology peers
Book Value per Share (MRQ)
0.4390USDUpdated Sep 26, 2026Total Assets
364.39MUSDvs all stocks (USD)
Total Current Assets
350.25MUSDFY2025 · Dec 31, 2025Total Liabilities
327.19MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.14MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
288.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
38.63MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
238.20MUSDFY2025 · Dec 31, 2025Other Short-term Investments
73.44MUSDFY2025 · Dec 31, 2025Accounts Receivable
33.85MUSDFY2025 · Dec 31, 2025Accounts Payable
3.87MUSDFY2025 · Dec 31, 2025Short-term Debt
2.08MUSDFY2025 · Dec 31, 2025Long-term Debt
12.03MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
276.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-772.56MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
37.21MUSDvs all stocks (USD)
52-Week Low
15.43USDUpdated Sep 26, 202652-Week High
72.36USDUpdated Sep 26, 202652-Week Change
228.75%vs all stocks
Beta
0.4080xvs all stocks
50-Day MA
55.47USDUpdated Sep 26, 2026200-Day MA
48.20USDUpdated Sep 26, 2026Avg 10-Day Volume
540.63KSharesUpdated Sep 26, 2026Avg 30-Day Volume
473.74KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-1.02USDUpdated Sep 26, 2026Other Income / Expense
5.43MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 53.4%, higher than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: 0.53Industry median: -0.38Industry P95: 0.40Peers compared: 260
Profit margin is 247%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 2.47Industry median: -0.48Industry P95: 0.42Peers compared: 260
Debt-to-equity is 25.47×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 25.47Industry median: 0.07Industry P95: 0.93Peers compared: 260
Price-to-book is 116.17×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 116.173Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 352,716,000Operating Cash Flow (USD, TTM): -105,118,000
Significant cash reserves alongside high leverageNotable
Cash (USD): 164,143,008Total Debt (USD): 269,588,000Debt-to-Equity: 25.47
Financial Health
Altman Z-Score 2.1: grey zoneSignificant
Altman Z-Score: 2.10
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.52B, above the global median of $1.18BNotable
Market cap (USD): 1,524,657,444Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
China Traditional Chinese Medicine Holdings Co. Limited
Tier 1ProductionApproval-Gated PipelineFlowInterface
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Edan Instruments Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Yamaichi Electronics Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Guangdong Silver Age Sci & Tech Co. Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated